Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cyclo-oxygenase-2 inhibitors - Nobex

Drug Profile

Research programme: cyclo-oxygenase-2 inhibitors - Nobex

Alternative Names: COX-2 inhibitors research programme - Nobex; Cyclo-oxygenase-2 inhibitors research programme - Nobex; NNB 001; NNB 004; NNB 005; Research programme: COX-2 inhibitors - Nobex

Latest Information Update: 31 Mar 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nobex Corporation
  • Class
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatic disorders

Most Recent Events

  • 31 Mar 2004 Discontinued - Preclinical for Rheumatic disorders in USA (PO)
  • 24 Jan 2001 New profile
  • 24 Jan 2001 Nobex's COX-2 inhibitors programme is available for licensing (http://www.nobexcorp.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top